Literature DB >> 3136623

Aggregation of human peripheral blood mononuclear cells by calcium ionophore A23187. Comparison with the aggregation of platelets and defective response in Glanzmann's thrombasthenia.

A M Cerbone1, G Di Minno, P Montemurro, C Iride, N Ciavarella, A Scillitani, N Semeraro.   

Abstract

Following exposure to calcium ionophore A23187, washed peripheral blood mononuclear cells (MNC) aggregated and formed thromboxane, like platelets. However, while aspirin strongly inhibited platelet aggregation and thromboxane formation, it had a little effect on the aggregation of MNC. In about 50% of the samples studied, aggregation of MNC was associated with the secretion of ATP. However studies in which exogenous ATP or ADP were used, suggested that the aggregation of MNC is independent of the secretion of nucleotides. MNC from 2 thrombasthenic patients failed to aggregate and bound 9-10 fold less radiolabelled fibrinogen than those from normals when challenged with A23187. However, fibrinogen, which plays a major role in the aggregation of platelets, did not appear to be involved in the aggregation of MNC. A differing behavior of these two types of cells was also found when the effect of plasma was studied on the aggregation response to A23187. Indeed, citrated plasma greatly enhanced the aggregation of platelets while it suppressed the response to MNC. This inhibitory effect of plasma was not detected when heparinized plasma was substituted for citrated plasma. We conclude that the aggregation of MNC in response to A23187 does not involve basic events known to play a major role in the aggregation of platelets. The response to A23187 may be an important probe for understanding basic mechanisms and pathophysiological significance of the aggregation of MNC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136623     DOI: 10.1007/bf01968096

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  23 in total

1.  Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes.

Authors:  D R Phillips; C S Jenkins; E F Lüscher; M Larrieu
Journal:  Nature       Date:  1975-10-16       Impact factor: 49.962

2.  Binding of fibrinogen to human monocytes.

Authors:  D C Altieri; P M Mannucci; A M Capitanio
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

3.  Interrelations of platelet aggregation and secretion.

Authors:  I F Charo; R D Feinman; T C Detwiler
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

4.  Platelet glycolytic enzymes: effect of cellular disruption procedures on activity.

Authors:  J C Doery; J Hirsh; G C De Gruchy
Journal:  Br J Haematol       Date:  1970-08       Impact factor: 6.998

5.  An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia.

Authors:  A T Nurden; J P Caen
Journal:  Br J Haematol       Date:  1974-10       Impact factor: 6.998

6.  Thromboxane synthesis and the platelet release reaction in Bernard-Soulier syndrome, thrombasthenia Glanzmann and Hermansky-Pudlak syndrome.

Authors:  C Malmsten; H Kindahl; B Samuelsson; S Levy-Toledano; G Tobelem; J P Caen
Journal:  Br J Haematol       Date:  1977-04       Impact factor: 6.998

7.  Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF).

Authors:  T Yasaka; L A Boxer; R L Baehner
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

8.  Specific binding of soluble fibrin to macrophages.

Authors:  L A Sherman; J Lee
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

9.  Absence of platelet membrane glycoproteins IIb/IIIa from monocytes.

Authors:  K J Clemetson; J L McGregor; R P McEver; Y V Jacques; D F Bainton; W Domzig; M Baggiolini
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

10.  Human monocytes are associated with the formation of fibrin.

Authors:  N Hogg
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.